Analysts See $1.76 EPS for Genmab A/S (GNMSF)

March 14, 2018 - By Ellis Scott

 Analysts See $1.76 EPS for Genmab A/S (GNMSF)

Analysts expect Genmab A/S (OTCMKTS:GNMSF) to report $1.76 EPS on March, 27.GNMSF’s profit would be $109.46 million giving it 29.83 P/E if the $1.76 EPS is correct. The stock increased 0.00% or $0.5 during the last trading session, reaching $210. About 1,570 shares traded or 76.21% up from the average. Genmab A/S (OTCMKTS:GNMSF) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company has market cap of $13.06 billion. The firm markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma ; and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). It has a 71.53 P/E ratio. The Company’s products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies.

More notable recent Genmab A/S (OTCMKTS:GNMSF) news were published by: which released: “Genmab 2017 Annual Report” on February 21, 2018, also with their article: “Genmab A/S” published on October 19, 2017, published: “Genmab Looks Attractive As Company Raises Its Full-Year Outlook” on December 20, 2017. More interesting news about Genmab A/S (OTCMKTS:GNMSF) were released by: and their article: “Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from …” published on January 22, 2018 as well as‘s news article titled: “After Soaring 3000% in 5 Years, Genmab Tests Stock-Market Habit” with publication date: December 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.